Stay updated with breaking news from Michaelr Cook. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Michael R. Cook, MD, discusses real-world data associated with the utilization of bridging therapy prior to treatment with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.
Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration.
Authors review the indications and contraindications of hyperbaric oxygen therapy in chronic wound management.